BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 10687982)

  • 1. Prostate cancer detection at low prostate specific antigen.
    Schröder FH; van der Cruijsen-Koeter I; de Koning HJ; Vis AN; Hoedemaeker RF; Kranse R
    J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
    J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.
    Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
    J Urol; 2017 Feb; 197(2S):S200-S207. PubMed ID: 28012755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
    Presti JC; Hovey R; Carroll PR; Shinohara K
    J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
    Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
    Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.
    Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
    J Urol; 1994 May; 151(5):1283-90. PubMed ID: 7512659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
    Lodding P; Aus G; Bergdahl S; Frösing R; Lilja H; Pihl CG; Hugosson J
    J Urol; 1998 Mar; 159(3):899-903. PubMed ID: 9474178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL.
    Kim HS; Jeon SS; Choi JD; Kim W; Han DH; Jeong BC; Seo SI; Lee KS; Lee SW; Lee HM; Choi HY
    Urology; 2010 Oct; 76(4):919-22. PubMed ID: 20303152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
    Catalona WJ; Richie JP; deKernion JB; Ahmann FR; Ratliff TL; Dalkin BL; Kavoussi LR; MacFarlane MT; Southwick PC
    J Urol; 1994 Dec; 152(6 Pt 1):2031-6. PubMed ID: 7525994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
    Luboldt HJ; Bex A; Swoboda A; Hüsing J; Rübben H;
    Eur Urol; 2001 Feb; 39(2):131-7. PubMed ID: 11223671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risks of prostate cancer detection by transrectal ultrasound guide biopsy in Thai men with abnormal prostatic-specific antigen or abnormal digital rectal examination.
    Leewansangtong S; Tantiwong A; Ratanarapee S; Nualyong C; Soontrapa S
    J Med Assoc Thai; 2000 Dec; 83(12):1519-24. PubMed ID: 11253893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
    Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
    J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.
    Roobol MJ; Steyerberg EW; Kranse R; Wolters T; van den Bergh RC; Bangma CH; Schröder FH
    Eur Urol; 2010 Jan; 57(1):79-85. PubMed ID: 19733959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnostic algorithm based on a multivariate model to reduce the percentage of negative prostatic biopsies in patients with changed PSA or suspicious rectal palpation].
    Valer Algarabel J; Agüera Fernández L; Adot Zurbano JM; Virseda Chamorro M; Marcos Díez J; Gómez López A; Alpuente Román C
    Actas Urol Esp; 2000; 24(7):549-59. PubMed ID: 11011445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Early diagnosis of prostate carcinoma with reference to the density of prostate-specific antigen].
    Schmid HP; Ravery V; Toublanc M; Boccon-Gibod L
    Schweiz Med Wochenschr; 1996 Sep; 126(36):1530-5. PubMed ID: 8927956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.